Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: Opioids

Neurontin Prescriptions Surge Amid Opioid Crisis

Cindy Devone-Pacheco  |  January 4, 2018

(Reuters Health)—Prescriptions for nerve pain medicines like Neurontin and Lyrica have more than tripled in recent years, driven by increased use among chronically ill older adults and patients already taking opioids, a U.S. study suggests. The proportion of U.S. adults prescribed Neurontin and other drugs in the same family of medicines climbed from 1.2% in…

Filed under:Drug Updates Tagged with:gabapentinoidsLyricanational opioid addiction epidemicNeurontinNeurontin prescription surgeopioid crisis

U.S. Life Expectancy Fell in 2016 as Opioid Overdoses Surged—CDC

Reuters Staff  |  December 26, 2017

NEW YORK (Reuters)—Life expectancy in the United States dipped in 2016 as the number of deaths due to opioid drug overdoses surged and total drug overdose deaths rose 21% to 63,600, the U.S. Centers for Disease Control and Prevention said on Thursday. Life expectancy fell to 78.6 years, a decrease of 0.1 year from 2015,…

Filed under:Uncategorized Tagged with:opioid crisisopioid drug overdosesU.S. Centers for Disease Control and PreventionU.S. opioid addiction epidemicUnited States life expectancy 2016

Opioid Painkiller Prescriptions May Run in Families

Lisa Rapaport  |  December 12, 2017

(Reuters Health)—When one person in a household gets prescribed opioids, the other people who live with them are more likely to get their own prescriptions for these narcotic painkillers, a U.S. study suggests. Researchers examined data on about 12.6 million people living in a household where someone was prescribed opioids and 6.4 million individuals in…

Filed under:AnalgesicsDrug Updates Tagged with:familyOpioid abuseopioid painkillersOpioids

Kentucky Accuses Endo of Contributing to Opioid Epidemic

Nate Raymond  |  November 7, 2017

(Reuters)—Kentucky accused units of Endo International Plc. on Monday of contributing to drug overdoses by deceptively marketing its painkiller Opana ER, in the latest lawsuit by state or local governments against the drugmaker amid an opioid epidemic. Kentucky Attorney General Steve Beshear said the lawsuit would seek to hold Endo responsible for illegally building a…

Filed under:AnalgesicsConditionsDrug UpdatesLegal UpdatesPain SyndromesProfessional Topics Tagged with:Chronic painlawsuitLegalOpioid abuseOpioidsPain

Trump Panel Urges More Treatment Options to Fight Opioid Crisis

Toni Clarke  |  November 2, 2017

(Reuters)—A panel convened by U.S. President Donald Trump to tackle the opioid crisis called on Wednesday for more treatment programs, tighter prescribing guidelines and additional drug courts to help reduce overdose deaths. The commission, led by New Jersey Governor Chris Christie, said the recommendations would require funding by Congress but did not recommend an amount….

Filed under:Legislation & Advocacy Tagged with:more treatment optionsnational opioid addiction epidemicNew Jersey Governor Chris Christieopioid crisis

New Jersey Sues OxyContin Maker, Links Marketing to Opioid Crisis

Jonathan Stempel  |  November 1, 2017

(Reuters)—New Jersey on Tuesday sued Purdue Pharma LP, accusing the OxyContin maker of contributing to the state’s opioid crisis through deceptive marketing to doctors and patients, including the elderly and the “opioid-naive.” Christopher Porrino, the New Jersey attorney general, faulted what he called a decade-long marketing campaign of “almost inconceivable callousness and irresponsibility, and said…

Filed under:Drug UpdatesLegal Updates Tagged with:deceptive marketingnational opioid addiction epidemicNew Jersey lawsuitopioid crisisOxyContin makerPurdue Pharma LP

Billionaire Insys Founder Charged in U.S. Opioid Bribe Case

Nate Raymond  |  October 27, 2017

BOSTON (Reuters)—The billionaire founder of Insys Therapeutics Inc was arrested on Thursday on U.S. charges he participated in a scheme to bribe doctors to prescribe a fentanyl-based cancer pain drug, marking a step by authorities to fight the opioid epidemic. John Kapoor, Insys’ majority shareholder who stepped down as chief executive in January, was charged…

Filed under:Legal Updates Tagged with:billionaire Insys founderCancerfentanyl-based cancer pain drugInsys Therapeutics IncJohn Kapoornational opioid addiction epidemicopioid crisisU.S. opioid bribe case

U.S. to Promote Use of Opioid Alternatives to Treat Addiction

Toni Clarke  |  October 26, 2017

(Reuters)—The U.S. Food and Drug Administration plans to encourage opioid addicts to use less harmful opioid drugs such as methadone and buprenorphine, a radical shift in policy that could agitate those in the addiction field who believe abstinence is the only effective treatment. Speaking before the House Committee on Energy and Commerce on Wednesday, FDA…

Filed under:Drug Updates Tagged with:addiction treatmentbuprenorphineFDA Commissioner Scott Gottliebmethadonenational opioid addiction epidemicopioid alternativesopioid crisisopioid substituteU.S. Food and Drug Administration (FDA)

Rhode Island Doctor Pleads Guilty to Opioid Kickback Scheme

Nate Raymond  |  October 26, 2017

BOSTON (Reuters)—A Rhode Island doctor pleaded guilty on Wednesday to charges he participated in a scheme to obtain kickbacks in exchange for writing prescriptions for an addictive fentanyl-based cancer pain drug produced by Insys Therapeutics Inc. The plea by Jerrold Rosenberg came amid ongoing investigations of Insys related to Subsys, an under-the-tongue spray that contains…

Filed under:EthicsLegal Updates Tagged with:Cancerfentanyl-based cancer pain drugguilty pleahealthcare fraudInsys Therapeutics IncJerrold Rosenbergnational opioid addiction epidemicopioid crisisopioid kickback schemeRhode Island doctor

New Jersey Sues Insys as Opioid Maker Settles with Massachusetts

Nate Raymond  |  October 5, 2017

BOSTON (Reuters)—New Jersey on Thursday accused Insys Therapeutics Inc of engaging in a fraudulent scheme to boost sales of a fentanyl-based cancer pain drug, as Massachusetts announced a $500,000 settlement with the drugmaker to resolve similar allegations. The lawsuit by New Jersey Attorney General Christopher Porrino accused Insys of illegally directing its sales force to…

Filed under:Drug UpdatesLegal Updates Tagged with:Cancerfentanyl-based cancer pain drugInsys Therapeutics IncNew Jersey Attorney General Christopher PorrinoNew Jersey lawsuitopioid crisis

  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • …
  • 20
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences